KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average) (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $61.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 1.39% year-over-year to $61.0 million; the TTM value through Dec 2025 reached $61.0 million, down 1.39%, while the annual FY2025 figure was $61.0 million, 1.39% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $61.0 million in Q4 2025 per JAZZ's latest filing, roughly flat from $61.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $63.7 million in Q2 2023 and bottomed at $56.5 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $61.6 million, with a median of $61.9 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 9.56% in 2022, then dropped 3.33% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $59.7 million in 2021, then rose by 4.77% to $62.5 million in 2022, then grew by 1.2% to $63.3 million in 2023, then fell by 2.3% to $61.8 million in 2024, then decreased by 1.39% to $61.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $61.0 million in Q4 2025, $61.0 million in Q3 2025, and $61.2 million in Q2 2025.